Can low omega-3 with omega-6 dominance prolong inflammation and allergic symptoms?

The biochemical role of omega-3 fatty acids as precursors for specialized pro-resolving mediators (SPMs) is a well-established mechanism in immunology. Research confirms that an imbalance in the ratio of omega-6 to omega-3 fatty acids can sustain inflammatory signaling and exacerbate allergic-type symptoms.

Mechanistic basis of inflammation resolution

Inflammation does not simply fade away; it is actively terminated through a process called "resolution." Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are the essential substrates for the synthesis of SPMs, including:

• Resolvins (E and D series): Derived from EPA and DHA, these molecules inhibit the further recruitment of neutrophils to the site of inflammation.
• Protectins and Maresins: These DHA-derived mediators promote "efferocytosis"—the clearance of cellular debris and apoptotic immune cells by macrophages—which is necessary to restore tissue homeostasis.
• Enzymatic Competition: Omega-3 and omega-6 fatty acids compete for the same cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. When omega-6 (arachidonic acid) dominates, the body preferentially produces pro-inflammatory 2-series prostaglandins and 4-series leukotrienes. A sufficient supply of omega-3 is required to shift enzymatic activity toward the production of pro-resolving mediators.

Clinical evidence and allergic symptoms

The dominance of omega-6 fatty acids contributes to a biochemical environment that favors prolonged inflammatory and allergic responses.

• Inflammatory Markers: High omega-6 to omega-3 ratios (often exceeding 15:1 in Western diets) are associated with elevated systemic biomarkers, including C-reactive protein (CRP), Interleukin-6 (IL-6), and TNF-alpha. Reducing this ratio to approximately 4:1 or lower has been shown to decrease these markers in clinical studies.
• Allergic Pathways: In allergic responses, omega-6-derived leukotrienes are primary mediators of symptoms like rhinitis and bronchial constriction. Preclinical and animal models demonstrate that increasing omega-3 intake can dampen these symptoms by producing 15-HEPE (a precursor to resolvins), which actively suppresses allergic airway inflammation.
• Effectiveness: In some models, the symptomatic relief provided by balancing these fatty acids was comparable to leukotriene receptor antagonists (e.g., montelukast), highlighting the practical significance of the omega-3/omega-6 balance in managing allergic signaling.

Bottom line

The claim is strongly supported by science. Omega-3 fatty acids provide the necessary molecular building blocks (SPMs) to actively "switch off" inflammation; a deficiency in omega-3 combined with a high omega-6 intake creates a pro-inflammatory state that delays resolution and may prolong allergic symptoms.